PURPOSE We studied the long-term outcomes of invasive micropapillary carcinoma (IMPCs) of the breast in relation to stromal tumor infiltrating lymphocytes (sTILs), prognostic biomarkers and clinicopathological features. METHODS Stage I-III IMPCs treated with upfront surgery at our institution (January 2000 and December 2016) were included. Central pathology review was performed and sTILs (including zonal distribution and hot spot analysis) and tumor-associated plasma cells (TAPC) were evaluated. Expression of P53, BCL2, FOXP3, and WT1, which are variably linked to breast cancer prognosis, was measured by immunohistochemistry using tissue microarrays. Time-to-event endpoints were distant recurrence free interval (DRFI) and breast cancer-specific survival (BCSS). RESULTS We included 111 patients of whom 59% were pure IMPCs. Standard clinicopathological features were comparable between pure and non-pure IMPCs. Overall, the mean sTILs level was 20% with higher proportion of sTILs present at the invasive front. There were no significant differences between pure- and non-pure IMPCs in sTILs levels, nor in the spatial distribution of the hot spot regions or in the distribution of TAPC. Higher sTILs correlated with worse DRFI (HR = 1.55; p = 0.0172) and BCSS (HR = 2.10; p < 0.001). CONCLUSIONS Clinicopathological features, geographical distribution of sTILs and TAPC are similar between pure and non-pure IMPCs. Despite a high proportion of grade 3 tumors and lymph node involvement, we observed a low rate of distant recurrences and breast cancer-related death in this cohort of stage I-III IMPCs treated with primary surgery. Caution in interpretation of the observed prognostic correlations is required given the very low number of events, warranting validation in other cohorts.

中文翻译：

---

评估浸润性微乳头状乳腺癌的间质肿瘤浸润淋巴细胞和免疫组织化学特征，并具有长期结果。

目的我们研究了乳腺浸润性微乳头状癌 (IMPC) 与间质瘤浸润淋巴细胞 (sTIL)、预后生物标志物和临床病理特征的长期结果。方法 包括在我们机构（2000 年 1 月和 2016 年 12 月）接受前期手术治疗的 I-III 期 IMPC。进行了中心病理学审查并评估了 sTIL（包括区域分布和热点分析）和肿瘤相关浆细胞 (TAPC)。P53、BCL2、FOXP3 和 WT1 的表达与乳腺癌预后有不同的关联，通过使用组织微阵列的免疫组织化学进行测量。事件发生时间终点是无远处复发间隔（DRFI）和乳腺癌特异性生存（BCSS）。结果 我们纳入了 111 名患者，其中 59% 是纯 IMPC。纯和非纯 IMPC 之间的标准临床病理特征具有可比性。总体而言，平均 sTILs 水平为 20%，其中侵入性前沿的 sTILs 比例更高。纯和非纯 IMPC 在 sTILs 水平、热点区域的空间分布或 TAPC 分布方面没有显着差异。较高的 sTIL 与较差的 DRFI（HR = 1.55；p = 0.0172）和 BCSS（HR = 2.10；p < 0.001）相关。结论 纯 IMPC 和非纯 IMPC 的临床病理特征、sTIL 和 TAPC 的地理分布相似。尽管 3 级肿瘤和淋巴结受累的比例很高，但我们观察到，在接受初次手术治疗的 I-III 期 IMPC 队列中，远处复发率和乳腺癌相关死亡率较低。